John Adeniji
Psychiatric/Mental Health · Redlands, CANPI 1003280892
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,315 of the $28,798 with a category attached, or 63.6%. It is spread thinly across 28 manufacturers, the largest accounting for just 23.7%. 2025 is the largest year on record at $12,254, more than ten times the $630 reported in 2021. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 933 payments — averaging $30.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$7K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$4K
- Teva Pharmaceuticals USA, Inc.$3K
- AbbVie$2K
- Alkermes, Inc.$2K
- Johnson & Johnson$2K
- plus $9K from 22 others
What the payments were for
- Consulting fees$3,29511%
- Speaking & faculty fees$4,93917%
- Travel & lodging$1,9147%
- Food & beverage$18,31564%
- Education$3351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 102 | $6,818 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 11 | $3,823 |
| Teva Pharmaceuticals USA, Inc. | 111 | $2,552 |
| AbbVie | 129 | $2,405 |
| Alkermes, Inc. | 99 | $1,968 |
| Johnson & Johnson | 92 | $1,925 |
| Biogen | 2 | $1,792 |
| Neurocrine Biosciences, Inc. | 71 | $1,554 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 63 | $1,358 |
| Lundbeck LLC | 73 | $1,197 |
| E.r. Squibb & Sons, L.L.C. | 35 | $775 |
| Indivior Inc. | 41 | $672 |
| Sunovion Pharmaceuticals Inc. | 38 | $449 |
| Idorsia Pharmaceuticals US Inc | 4 | $188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $174 |
| Axsome Therapeutics, Inc. | 4 | $167 |
| Almatica Pharma LLC | 6 | $143 |
| Merck | 7 | $123 |
| Supernus Pharmaceuticals, Inc. | 6 | $122 |
| Vanda Pharmaceuticals Inc. | 6 | $108 |
| Corium, LLC | 4 | $97 |
| GSK | 5 | $84 |
| Sage Therapeutics, LLC | 3 | $79 |
| Ironshore Pharmaceuticals Inc. | 3 | $64 |
| Bausch Health US, LLC | 4 | $61 |
| Collegium Pharmaceutical, Inc. | 3 | $51 |
| Janssen Scientific Affairs, LLC | 1 | $29 |
| Eisai Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$5,049
- ABILIFY MAINTENA$3,514
- LYBALVI$1,398
- Zurzuvae$672
- ARISTADA$478
- AUSTEDO$371
- INGREZZA$306
- COBENFY$257
- UZEDY$250
- VRAYLAR$249
- SPRAVATO$230
- CAPLYTA$130
- Auvelity$125
- INVEGA SUSTENNA$125
- ARISTADA INITIO$119
How this compares
$28,798 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 199 | $304,772 |
| Abilify MaintenaAripiprazole | 59 | $158,881 |
| IngrezzaValbenazine Tosylate | 16 | $126,332 |
| UzedyRisperidone | 37 | $113,046 |
| Invega SustennaPaliperidone Palmitate | 36 | $103,737 |
| AustedoDeutetrabenazine | 14 | $95,837 |
| PerserisRisperidone | 37 | $95,407 |
| VraylarCariprazine Hcl | 38 | $60,405 |
| AristadaAripiprazole Lauroxil | 17 | $56,633 |
| LybalviOlanzapine/Samidorphan Malate | 26 | $38,326 |
| TrintellixVortioxetine Hydrobromide | 29 | $27,387 |
| BelsomraSuvorexant | 56 | $24,570 |
| Aripiprazole | 156 | $16,147 |
| ProzacFluoxetine Hcl | 14 | $10,287 |
| Quetiapine Fumarate | 687 | $9,898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $6,818 | $463,653258 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy, Austedo | $2,552 | $208,88351 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,554 | $126,33216 claims |
| Johnson & JohnsonInvega Sustenna | $1,925 | $103,73736 claims |
| Indivior Inc.Perseris | $672 | $95,40737 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,968 | $94,95943 claims |
| AbbVieVraylar | $2,405 | $60,40538 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $174 | $27,38729 claims |
| MerckBelsomra | $123 | $24,57056 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $188 | $7,00713 claims |
| Almatica Pharma LLCSertraline Hcl | $143 | $3,090532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Redlands
- Liberty MaciasRedlands$288K
- Magnus IhemeduRedlands$15K
- Jogendra SinghRedlands$13K
- Akta PatelRedlands$11K
- Linda JacksonRedlands$11K
- Carey MartinMillbrae$745K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.